Clinically, CRS usually develops within the first few days after infusion—earlier with CD28‐based products, and somewhat later with 4‐1BB‐based products—and may range from isolated fever to life‐threatening shock and hypoxemic respiratory failure [9]. The gene discussed is CD28; the disease is congenital rubella syndrome.